SK Biopharmaceuticals

SK Biopharmaceuticals, a Pharmaceutical Preparation Manufacturing company headquartered in KR, reported its 2023 emissions. For 2023, the company's Scope 1 emissions were 433,000 kg CO2e, Scope 2 emissions were 1,046,000 kg CO2e, and Scope 3 emissions were 11,882,000 kg CO2e. The total sum of Scope 1, 2, and 3 emissions for 2023 was approximately 13,361,000 kg CO2e.

In 2022, SK Biopharmaceuticals' Scope 1 emissions were 425,000 kg CO2e, Scope 2 emissions were 936,000 kg CO2e, and Scope 3 emissions were 6,547,000 kg CO2e, resulting in a total of approximately 7,908,000 kg CO2e.

For 2021, the company disclosed Scope 1 emissions of 394,000 kg CO2e and Scope 2 emissions of 955,000 kg CO2e. In 2020, Scope 1 emissions were 313,000 kg CO2e and Scope 2 emissions were 898,000 kg CO2e. In 2019, Scope 1 emissions were 282,000 kg CO2e and Scope 2 emissions were 823,000 kg CO2e. The earliest reported data for 2018 shows Scope 1 emissions of 328,000 kg CO2e and Scope 2 emissions of 841,000 kg CO2e. Scope 3 data was not disclosed for years prior to 2022.

SK Biopharmaceuticals' SBTi reduction targets are cascaded from its ultimate parent, SK Inc. The company has not provided details on specific reduction initiatives or climate pledges.